Elacestrant in ER+, HER2- MBC with ESR1-mutated tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor and in Clinical Subgroups.

Auteurs

Bardia A, Cortes J, Bidard FC, Neven P, Garcia-Saenz J, Aftimos P, O'Shaughnessy J, Lu J, Tonini G, Scartoni S, Paoli A, Binaschi M, Wasserman T, Kaklamani V

  • Date de publication

    August 2024

  • Type

    Article

  • Review

    Clin Cancer Res

  • Researcher's name

    AFTIMOS PHILIPPE

  • Hôpital

    Institut Jules Bordet

  • Service

    Médecine Oncologique

  • PMID

    39087959

  • DOI

    10.1158/1078-0432.CCR-24-1073